Nephrostomy insertion for patients with bilateral ureteric obstruction caused by prostate cancer

Nariculam, Joseph; Murphy, D.; Jenner, Christopher; Sellars, N.; Gwyther, Stephen J.; Gordon, Steve; Swinn, M.

doi:10.1259/bjr/38306763

Cited by 35 publications

(52 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mokhmalji et al showed a success rate of 100% in PCN group but only 80% rate was achieved in the DJS group. 3 Yagci et al also show a 10,11 Total Leukocyte count was normal in 44% of the patients in our study and raised in 56%. Out of these 32% patients underwent percutaneous nephrostomy and 16% underwent ureteric stenting.…”

Section: Resultssupporting

confidence: 72%

Percutaneous nephrostomy or double J stenting, which is better modality for obstructive uropathy-a descriptive study

2016

View full text Add to dashboard Cite

Section: Resultssupporting

confidence: 72%

Percutaneous nephrostomy or double J stenting, which is better modality for obstructive uropathy-a descriptive study

2016

View full text Add to dashboard Cite

“…injury (45,46). Deteriorated kidney tissue loses its capability to maintain its naturally functions resulting in disturbances in urine electrolytes (Table III).…”

Section: Cancer Patients Healthy Controls ---------------------------mentioning

confidence: 99%

Determination of common urine substances as an assay for improving prostate carcinoma diagnostics

et al. 2014

View full text Add to dashboard Cite

Abstract.Recently, interest in the identification of non-invasive markers for prostate carcinoma detectable in the urine of patients has increased. In this study, we monitored the abundance of potential non-invasive markers of prostate carcinoma such as amino acid sarcosine, involved in the metabolism of amino acids and methylation processes, ongoing during the progression of prostate carcinoma. In addition, other potential prostate tumor markers were studied. The most significant markers, prostate-specific antigen (PSA) and free PSA (fPSA), already used in clinical diagnosis, were analyzed using an immunoenzymometric assay. Whole amino acid profiles were also determined to evaluate the status of amino acids in patient urine samples and to elucidate the possibility of their utilization for prostate carcinoma diagnosis. To obtain the maximum amount of information, the biochemical parameters were determined using various spectrophotometric methods. All results were subjected to statistical processing for revealing different correlations between the studied parameters. We observed alterations in most of the analyzed substances. Based on the results obtained, we concluded that the specificity of prostate carcinoma diagnosis could be improved by determination of common urine metabolites, since we compiled a set of tests, including the analysis of sarcosine, proline, PSA and uric acid in the urine. These metabolites were not observed in the urine obtained from healthy subjects, while their levels were elevated in all patients suffering from prostate carcinoma.

show abstract

“…Multiple studies have shown both stents and nephrostomy tubes are effective methods to restore kidney function after ureteric obstruction. 2,3,10,[16][17][18][19] Advancements in and availabil- There was a trend toward a decreasing percentage in the number of patients presenting with BUO secondary to cervical cancer compared with 1982. It is possible that aggressive screening for cervical cancer over the past 25 years contributed to this observation.…”

mentioning

confidence: 99%

Acute reversible kidney injury secondary to bilateral ureteric Obstruction

Organ¹,

Norman²

2011

cuaj

View full text Add to dashboard Cite

Background: Acute reversible kidney injury (ARKI) secondary to bilateral ureteric obstruction (BUO) is a common urological problem. Our goals were to describe the etiology, management and outcomes of such patients identified between 2006 and 2009 and to compare them with a similar historical study published in 1982. Methods: Chart review was performed on 49 patients with AKRI secondary to BUO. ARKI was defined as ≥33% decrease in serum creatinine after intervention. Those with malignant and benign causes of obstruction were identified and management and outcome data were collected. Results: Of these 49 patients, 83% had BUO secondary to malignancy, 28% of these presenting for the first time. Prevalence of bladder cancer was increased (p = 0.04) and cervix trended lower (p = 0.07) compared with the earlier study; prostate cancer was unchanged (p = 0.51). The average survival was 239 days; 90% of patients died within a year after presenting with BUO from a malignant etiology. Compared with the 1982 group, there were trends towards a decrease in the frequency of retroperitoneal fibrosis (p = 0.08) and an increase in bilateral ureteric calculi (p = 0.16) in the benign group. Conclusions: Patients with ARKI secondary to BUO most likely have an underlying malignancy, with almost a third of them being diagnosed for the first time. Prevalence of bladder cancer increased while cervical cancer trended lower. The cause for the former is unclear; the latter may be due to aggressive screening. Prostate cancer remained unchanged despite the widespread implementation of prostate-specific antigen testing. Patients with an underlying malignancy do poorly and those with a newly diagnosed malignancy do worst. Those with ARKI secondary to benign causes did well.

show abstract

Nephrostomy insertion for patients with bilateral ureteric obstruction caused by prostate cancer

Cited by 35 publications

References 22 publications

Percutaneous nephrostomy or double J stenting, which is better modality for obstructive uropathy-a descriptive study

Percutaneous nephrostomy or double J stenting, which is better modality for obstructive uropathy-a descriptive study

Determination of common urine substances as an assay for improving prostate carcinoma diagnostics

Acute reversible kidney injury secondary to bilateral ureteric Obstruction

Contact Info

Product

Resources

About